Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis
Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.
Clinical Scorecard: Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis
At a Glance
Category Detail
Condition Relapsing Multiple Sclerosis Key Mechanisms Observational registry to track outcomes, safety, and patient experience with BRUMVI. Target Population Patients with confirmed multiple sclerosis starting BRUMVI. Care Setting Real-world clinical practice.
Key Highlights
Observational registry collecting real-world data on BRUMVI. Focus on outcomes, safety, and patient experience over 192 weeks. Eligibility includes confirmed MS diagnosis and no prior BRUMVI infusions. Guideline-Based Recommendations
Diagnosis
Confirmed diagnosis of multiple sclerosis. Management
Patients should be prescribed BRUMVI and not have received prior infusions. Monitoring & Follow-up
Participants complete health questionnaires and brief assessments. Risks
Exclusion for recent live vaccines and active infections. Patient & Prescribing Data
Patients with relapsing multiple sclerosis starting BRUMVI.
Registry aims to gather data on the efficacy and safety of BRUMVI in everyday practice.
Clinical Best Practices
Continue usual clinical care while participating in the registry. Ensure eligibility criteria are met before referral. Related Resources & Content
